Malignant Cerebellar Neoplasm
Malignant cerebellar neoplasms most frequently harbor alterations in PTCH1, KMT2D, CTNNB1, TP53, and SMO .
KMT2D Mutation, CTNNB1 Mutation, TP53 Mutation, PTCH1 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in malignant cerebellar neoplasm .
There is 1 clinical trial for malignant cerebellar neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant cerebellar neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
Paxalisib is the most common intervention in malignant cerebellar neoplasm clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.